en · de · es · pt
peptide-index.peptides5388.com › Blog › Background And Research Status — Reference Sheet

Background And Research Status — Reference Sheet

By Editorial Desk · published 2026-02-11 · last reviewed 2026-03-28 · Blog

Everything below concerns NR1D2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

Notes from published material

238U(22Ne,xn)260−xNo (x=4,5,6) This reaction was first studied in 1964 at FLNR. The team were able to detect decays from 252Fm and 250Fm. The 252Fm activity was associated with an ~8 s half-life and assigned to 256102 from the 4n channel, with a yield of 45 nb. They were also able to detect a 10 s spontaneous fission activity also tentatively assigned to 256102. Further work in 1966 on the reaction examined the detection of 250Fm decay using chemical separation and a parent activity with a half-life of ~50 s was reported and correctly assigned to 254102. They also detected a 10 s spontaneous fission activity tentatively assigned to 256102. The reaction was used in 1969 to study some initial chemistry of nobelium at the FLNR. They determined eka-ytterbium properties, consistent with nobelium as the heavier homologue. In 1970, they were able to study the SF properties of 256No. In 2002, Patin et al. reported the synthesis of 256No from the 4n channel but were unable to detect 257No. The cross section values for the 4-6n channels have also been studied at the FLNR.

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, monoclonal antibodies, and living medicines used in cell therapy. Biopharmaceuticals can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is often used more restrictively to mean biopharmaceuticals that are produced using recombinant DNA technology. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.

== Related products == Waferboard belongs to the subset of reconstituted wood panel products called flakeboards. It is a structural material made from rectangular wood flakes of controlled length and thickness bonded together with waterproof phenolic resin under extreme heat and pressure. The layers of flakes are not oriented, which makes it easier to manufacture. Waferboard is used as a material to build cheap furniture. This type of furniture is usually laminated. Materials other than wood have been used to produce products similar to OSB. Oriented structural straw board is an engineered board made by splitting straw and formed by adding P-MDI adhesives and then hot compressing layers of straw in specific orientations. Strand board can also be made from bagasse.

The hemolymph, pericardial fluid and urine of cephalopods, including the common octopus, are all isosmotic with each other, as well as with the surrounding sea water. It has been suggested that cephalopods do not osmoregulate, which would indicate that they are conformers. This means that they adapt to match the osmotic pressure of their environment, and because there is no osmotic gradient, there is no net movement of water from the organism to the seawater, or from the seawater into the organism. Octopuses have an average minimum salinity requirement of 27 g/L (0.00098 lb/cu in), and that any disturbance introducing significant amounts of fresh water into their environment can prove fatal. In terms of ions, however, a discrepancy does seem to occur between ionic concentrations found in the seawater and those found within cephalopods. In general, they seem to maintain hypoionic concentrations of sodium, calcium, and chloride in contrast to the salt water. Sulfate and potassium exist in a hypoionic state, as well, with the exception of the excretory systems of cephalopods, where the urine is hyperionic. These ions are free to diffuse, and because they exist in hypoionic concentrations within the organism, they would be moving into the organism from the seawater. The fact that the organism can maintain hypoionic concentrations suggests not only that a form of ionic regulation exists within cephalopods, but also that they also actively excrete certain ions such as potassium and sulfate to maintain homeostasis. O.

== External links == Nanodisc Technology from the Stephen Sligar laboratory HDL and Nanodiscs an overview of nanodisc technology at UIUC Phospholipid Bilayer Nanodiscs A summary from the Atkins lab at the University of Washington SMA native nanodiscs website International research community website using SMA or other polymers (DIBMA for e.g.) as an alternative to conventional detergents and synthetic lipid environment found in MSP-Nanodisc.

Sources: en.wikipedia.org

Further detail

This response is activated by the binding of complement proteins to carbohydrates on the surfaces of microbes, or to antibodies that have attached to these microbes, which creates a cell signal that triggers a rapid killing response, whose speed is significantly amplified after sequential proteolytic activation of complement protease molecules, controlled by positive feedback. The cascade results in the production of peptides that attract immune cells; increase vascular permeability; and opsonize the surface of a pathogen, marking it for destruction. Complement binding can also kill cells directly by disrupting their plasma membrane via a membrane attack complex.

=== Sterilization of biomedical materials === Supercritical CO2 is an alternative for thermal sterilization of biological materials and medical devices with combination of the additive peracetic acid (PAA). Supercritical CO2 does not sterilize the media, because it does not kill the spores of microorganisms. Moreover, this process is gentle, as the morphology, ultrastructure and protein profiles of inactivated microbes are preserved.

Ruminant animals can obtain protein from at least some forms of non-protein nitrogen (NPN) through fermentation by their rumen bacteria, hence NPN is often added to their diet to supplement protein. Nonruminants such as cats, dogs and pigs (and humans) cannot utilize NPN. NPN are given to ruminants in the form of pelleted urea, ammonium phosphate and/or biuret. Sometimes slightly polymerized special urea-formaldehyde resin or a mixture of urea and formaldehyde (both are also known as formaldehyde-treated urea) is used in place of urea, because the former provides a better control on the nitrogen release. This practice is carried out in China and other countries, such as Finland, India and France. Cyanuric acid has also been used as NPN. For example, Archer Daniels Midland manufactures an NPN supplement for cattle, which contains biuret, triuret, cyanuric acid and urea. FDA permits a certain amount of cyanuric acid to be present in some additives used in animal feed and also drinking water. Melamine use as NPN for cattle was described in a 1958 patent. In 1978, however, a study concluded that melamine "may not be an acceptable nonprotein N source for ruminants", because its hydrolysis in cattle is slower and less complete than other nitrogen sources such as cottonseed meal and urea. In China, it is known that ground urea-formaldehyde resin is a common adulterant in feed for non-ruminants. Domestically it is often sold under the euphemism "protein essence" (蛋白精) and is described as "one kind of new proteinnitrogen feed additive".

Filiform papillae (from Latin filum 'thread') are the most numerous of the lingual papillae. They are fine, small, cone-shaped papillae found on the anterior surface of the tongue. They are responsible for giving the tongue its texture and are responsible for the sensation of touch. Unlike the other kinds of papillae, filiform papillae do not contain taste buds. They cover most of the front two-thirds of the tongue's surface. They appear as very small, conical or cylindrical surface projections, and are arranged in rows which lie parallel to the sulcus terminalis. At the tip of the tongue, these rows become more transverse. Histologically, they are made up of irregular connective tissue cores with a keratin–containing epithelium which has fine secondary threads. Heavy keratinization of filiform papillae, occurring for instance in cats, gives the tongue a roughness that is characteristic of these animals. These papillae have a whitish tint, owing to the thickness and density of their epithelium. This epithelium has undergone a peculiar modification as the cells have become cone–like and elongated into dense, overlapping, brush-like threads. They also contain a number of elastic fibers, which render them firmer and more elastic than the other types of papillae. The larger and longer papillae of this group are sometimes termed papillae conicae.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network